國藥現代(600420.SH):全資子公司獲得化學原料藥上市申請批准通知書
格隆匯1月7日丨國藥現代(600420.SH)公佈,全資子公司國藥集團工業有限公司(以下簡稱國藥工業)收到國家藥品監督管理局核准簽發的《化學原料藥上市申請批准通知書》,批准原料藥鹽酸納布啡上市申請。鹽酸納布啡是κ阿片受體激動劑和μ阿片受體拮抗劑,是一種強效中樞鎮痛劑。相關製劑產品鹽酸納布啡注射液主要作為複合麻醉時誘導麻醉的輔助用藥,也應用於緩解中至重度疼痛。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.